GPT and chronic kidney disease: For example, Silveira et al found that PRP administration (500 mg/d for 12 months) could prevent the increase of serum ALT in patients with chronic kidney disease.66 The discrepancy between the findings of studies may be due to differences in dosages of PRP, duration of the supplementation, and differences in clinical conditions.